D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging.
about
Clinical application of a 3D ultrasound-guided prostate biopsy systemRole of magnetic resonance imaging in defining a biopsy strategy for detection of prostate cancerCancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screeningTargeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancerIntegration of multiparametric MRI into active surveillance of prostate cancer.Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extension.Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathwayImaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session.Prostate biopsy for the interventional radiologistMRI-targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naïve men.Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging.Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up.Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies.Standardized Reporting of Prostate MRI: Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and Version 2Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion deviceTransatlantic Consensus Group on active surveillance and focal therapy for prostate cancerImaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical OverviewLow suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancerThe role of imaging in the diagnosis of primary prostate cancer.Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer.Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?Focal cryotherapy in the treatment of localized prostate cancer.Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.Magnetic resonance imaging-guided prostate biopsy: present and futureMRI-guided biopsies and minimally invasive therapy for prostate cancer.Comparison of Multiparametric and Biparametric MRI in First Round Cognitive Targeted Prostate Biopsy in Patients with PSA Levels under 10 ng/mL.Clinical and multiparametric MRI signatures of granulomatous prostatitis.Risk stratification of prostate cancer utilizing apparent diffusion coefficient value and lesion volume on multiparametric MRI.Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer.Is negative multiparametric magnetic resonance imaging really able to exclude significant prostate cancer? The real-life experience.Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?Impact of magnetic resonance imaging-guided prostate biopsy in the supine position on the detection of significant prostate cancer in an inhomogeneous patient cohort.Prostate diffusion imaging with distortion correctionProstate cancer detection using multiparametric 3 - tesla MRI and fusion biopsy: preliminary results.Current Ability of Multiparametric Prostate Magnetic Resonance Imaging and Targeted Biopsy to Improve the Detection of Prostate Cancer.Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance.PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples.
P2860
Q24608010-390F68C3-1E97-4099-8645-C341E6F3D7BAQ26998938-EDDBDB63-22EB-45F2-AE75-4CF05AE955A7Q27001043-5E0B2CC5-AD03-41FE-B72B-1B03BD3033ACQ27027567-CA9B7780-1E01-470B-8383-76515A8072F0Q30249514-82E0B901-1678-412E-9F2E-AD50B7E3452EQ30882787-0257BBE2-BD64-46F4-B9AE-67DF440EC9EEQ34761435-2A445279-FF80-4782-B93B-557FD57C5E8EQ34893798-A956C738-8AB3-4046-8141-F4A7644A3CC7Q35019408-4D50B1D5-7819-4F94-A963-4AF2A93F3700Q35068260-1FA20078-6984-48B8-A5D3-D55AC705A2C7Q35354750-1E3C4095-64EE-45F4-A2BD-9138BDC59C21Q35720507-E6786E85-0672-4D90-888C-A59E5F1D0A70Q35852107-CD02EE80-79C1-4CDD-85A3-9C144675928AQ36140880-649B1C04-151C-441C-9AA5-D69ACCB1687AQ36386904-D12F4F13-9927-4549-B95A-EF5CE3693274Q36579232-BE991EC3-E6DC-4D11-86C2-DA883E7117A5Q36928846-228FA880-1C7E-404D-988D-0BD34A725680Q36979944-2005F3AD-73E5-4C46-A102-A344762E62F5Q37254919-4C0A4ADE-7519-49C9-8451-410086683775Q37708182-083C5777-B9CA-45D7-8EF2-1D9CFE1CBE08Q37975227-5C0DF204-9049-4987-899E-D203D79BAB96Q38008282-8D1E343B-B9D1-4663-AEB4-2CA9F01E21FFQ38118055-B8917898-4562-426E-99EC-64BDA129231CQ38180533-E64C7B7B-E011-4B47-88DD-FC2FC3300164Q38322905-F7079975-B6E2-4EFF-AD8E-72813D9F0315Q38545811-DB9A43A4-5B8F-41CE-9183-E8F01790C39AQ38632565-E0C62D5B-2BAB-4AEE-8AE5-6276F410F2C6Q38753165-900C329F-653C-4284-ACFB-5C9CBD51167FQ38842683-24900385-5240-42D8-A1E3-301F9F7159E3Q39391979-E28507AB-1D61-4E0C-A20D-E34DF4E90BE0Q39401117-DD517F3D-E98D-44B8-A3E9-7DA9ECC11DB4Q40199490-A7C39E41-B767-43B5-8E46-718D214EE4ADQ40224363-6ACF59C8-BD3F-4172-9F97-C8DD2C63D89EQ40328097-A3BAB520-D9CC-4067-B12C-59397EC53C87Q40684010-480052E0-FE17-486A-96ED-F18484BD4E53Q41478717-324AFEF3-F6C1-4A31-9D26-F2094C0AE738Q42105461-8AE3B332-9482-437E-A30D-9115F886E595Q46790909-D72D2FBA-5962-4FA1-91A8-C65F9ED3076CQ48263594-EBAABC2D-2EFE-4F45-8179-B7F6BA785544Q54549406-1605E2D3-02ED-4240-BCF3-2EFDFFE8486E
P2860
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
D'Amico risk stratification co ...... ic magnetic resonance imaging.
@ast
D'Amico risk stratification co ...... ic magnetic resonance imaging.
@en
type
label
D'Amico risk stratification co ...... ic magnetic resonance imaging.
@ast
D'Amico risk stratification co ...... ic magnetic resonance imaging.
@en
prefLabel
D'Amico risk stratification co ...... ic magnetic resonance imaging.
@ast
D'Amico risk stratification co ...... ic magnetic resonance imaging.
@en
P2093
P2860
P50
P1476
D'Amico risk stratification co ...... ic magnetic resonance imaging.
@en
P2093
Angelo A Baccala
Ardeshir R Rastinehad
Baris Turkbey
Gennady Bratslavsky
Joanna Shih
Jochen Kruecker
Juan M Proano
Julia K Locklin
Neil D Glossop
Peter A Pinto
P2860
P304
P356
10.1016/J.JURO.2010.10.076
P407
P577
2011-01-15T00:00:00Z